Pharma-Bio Serv Announces Benefits for the Quarter Finished January 31, 2023

DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2023 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Organization”) (OTCQB:PBSV), a compliance, venture administration and engineering transfer assistance consulting firm that delivers providers to the pharmaceutical, biotechnology, chemical, health care device, beauty, food items and allied products industries, right now declared that revenues for the quarter finished January 31, 2023 were being around $4.2 million, a net lower of about $.8 million when as opposed to the very same period of time past year. Net income for the quarter finished January 31, 2023 was somewhere around $.4 million, an boost of approximately $.1 million when when compared to the very same period of time final yr.

“This quarter we were being in a position to properly optimize our assets in much more profitable markets. This strategy yielded a good result on our all round gross income percentage. We system to carry on maximizing our means to give improved profitability,” said Mr. Sanchez, Main Government Officer of the Firm.

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv providers the Puerto Rico, United States, Europe and Latin The united states markets. Pharma-Bio Serv’s main organization is Food and drug administration and intercontinental businesses regulatory compliance consulting relevant solutions. The Firm’s world wide crew contains major engineering and everyday living science professionals, excellent assurance supervisors and administrators.

Ahead-On the lookout Statements

This information release incorporates “forward-wanting statements” in the which means of the U.S. federal securities guidelines, which statements may possibly involve data with regards to the programs, intentions, anticipations, long term economical performance, or potential working overall performance of Pharma-Bio Serv. Ahead-wanting statements are primarily based on the expectations, estimates, or projections of management as of the date of this earnings announcement. While Pharma-Bio Serv’s administration believes these anticipations, estimates, or projections to be acceptable as of the date of this earnings announcement, forward-searching statements are inherently topic to sizeable business enterprise risks, financial uncertainties, and aggressive uncertainties, and other aspects, which could bring about its real final results or performance to vary materially from what may well be expressed or implied in the ahead-wanting statements. Essential variables that could lead to Pharma-Bio Serv’s genuine benefits or performance to vary materially from the ahead-looking statements involve individuals established forth in the “Danger Variables” section of Pharma-Bio Serv’s Yearly Report on Type 10-K for the 12 months ended October 31, 2022, and in its other filings with the Securities and Exchange Commission, which filings are available on Pharma-Bio Serv disclaims any intention or obligation to update or revise any ahead-seeking statements to reflect subsequent situations and instances, besides to the extent essential by relevant law.

Firm Get hold of:

Pedro J. Lasanta
Chief Monetary Officer
787 278 2709

Supply: Pharma-Bio Serv, Inc.

See source model on results-for-the-Quarter-Ended-January-31-2023

website link